A qualitative research exploring the experiences of patients receiving immune checkpoint inhibitors for advanced lung cancer.

Support Care Cancer

Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China.

Published: July 2023

Purposes: In patients with advanced lung cancer, immune checkpoint inhibitors (ICIs) dramatically extended survival. We aimed to investigate the experiences of patients with advanced lung cancer who are receiving ICIs, with a focus on perceptions and sentiments on ICIs, to inform future research and clinical care.

Methods: Patients were recruited from January to July 2022 at Tianjin Medical University Hospital Cancer Institute & Hospital. The method of purposive sampling was used. Patients with stage IV lung cancer who were taking ICIs as a single therapy were recruited. Data were gathered using semi-structured and face-to-face interview. An inductive approach to analysis was used.

Results: Of the 42 eligible patients, 27 were invited, 20 agreed to participate, and ultimately 17 patients completed the interview. A total of 5 themes were extracted: suffered from adverse effects but generally tolerable; focus on survival, hope, and expectation; uncertainty about durability of response and the future; poor knowledge and attitude of ICIs; and financial stress and guilt over family.

Conclusion: These findings make an important contribution to healthcare professionals' understanding of what it is like to be a patient with advanced lung cancer who is receiving ICIs. In general, the experience of immunotherapy is different from that of chemotherapy; financial and family pressures and uncertainty issues are likely to be heavier in this population. Oncology specialist nurses should provide tailored education to improve the patient's knowledge of immunotherapy, especially to improve risk awareness of immune-related adverse events and objective prognosis expectations.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-023-07965-3DOI Listing

Publication Analysis

Top Keywords

lung cancer
20
advanced lung
16
experiences patients
8
immune checkpoint
8
checkpoint inhibitors
8
patients advanced
8
cancer receiving
8
receiving icis
8
patients
7
cancer
6

Similar Publications

The redox imbalance, caused by depletion or generation of reactive oxygen species (ROS), is a key mechanism by which metal complexes exert anticancer effects. Carbidopa has shown the ability to inhibit the MDA-MB-231 cell line, a highly aggressive triple-negative human breast adenocarcinoma, by inducing reductive stress. The metal complex of carbidopa with zinc (ZnCarbi) was designed to modify carbidopa's structure and exhibited increased cytotoxicity against MDA-MB-231 cells.

View Article and Find Full Text PDF

Improving search strategies in bibliometric studies on machine learning in renal medicine.

Int Urol Nephrol

December 2024

Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37, Guoxue Lane, Wuhou District, Chengdu, 610041, Sichuan Province, China.

This paper evaluated the bibliometric study by Li et al. (Int Urol Nephrol, 2024) on machine learning in renal medicine. Although the study claims to summarize the forefront trends and hotspots in this field, several key issues require further clarification to effectively guide future research.

View Article and Find Full Text PDF

RASGEF1C as a novel prognostic biomarker for LUAD.

Discov Oncol

December 2024

Department of Thoracic Surgery, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong New Area, Shanghai, China.

Lung adenocarcinoma (LUAD) is a common histologic lung cancer with high morbidity and mortality, and most patients have distant metastases at diagnosis. RasGEF Domain Family Member 1C (RASGEF1C) could regulated Alzheimer's disease. However, its function in various cancers, including LUAD, is poorly understood.

View Article and Find Full Text PDF

Purpose: Lung cancer remains one of the most diagnosed cancers in Canada and continues to be the leading cause of cancer deaths in Canada, responsible for 25% of all cancer deaths. Prior studies consistently report poor experiences of people with lung cancers. The study purpose was to explore the reasons for consistently poorer reported experience of people with lung cancer compared to people with gastrointestinal cancers, who previously have reported positive cancer care experiences within the same context, and to better understand key differences that influence patient experience.

View Article and Find Full Text PDF

An AI dose-influence matrix engine for robust pencil beam scanning protons therapy.

Med Phys

December 2024

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.

Background: Rapid planning is of tremendous value in proton pencil beam scanning (PBS) therapy in overcoming range uncertainty. However, the dose calculation of the dose influence matrix (D) in robust PBS plan optimization is time-consuming and requires substantial acceleration to enhance efficiency.

Purpose: To accelerate the D calculations in PBS therapy, we developed an AI-D engine integrated into our in-house treatment planning system (TPS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!